Manchester-based Synexus, the world’s largest company responsible for the recruitment and running of clinical trials, is now in discussions with a number of sponsors with a view to undertaking further MCI trials according to Chief Executive, Dr Christophe Berthoux: “We have seen an increase in interest from sponsors who are investing significant sums of money into research for new treatments for MCI. Sponsors want to partner with clinical trials companies that actually deliver the number of patients needed to get their study underway, within the time frame agreed at the outset. Using our network of 26 Dedicated Research Centres, Synexus does this. That’s why we’re being approached more frequently now, to help with MCI studies.”
According to the World Alzheimer Report published last September, there are already just under 36 million people in the world with dementia. This number is expected to increase to around 66 million in twenty year’s time and with it the soaring cost of health and social care needed to provide adequate care for people living with this debilitating condition.
It’s no surprise, says Dr Berthoux, that pharma and biotech companies are turning their research and development focus to conditions such as MCI, dementia and Alzheimer’s Disease: “The latest World Alzheimer Report says that if dementia care were a country, it would be the world’s 18th largest economy’. That’s a huge future cost burden for healthcare budgets across the world and delivering successful, efficient clinical trials is one way the pharmaceutical industry can help bring new and improved treatments to the millions of patients who need them.”
Synexus notes:
Synexus® headquartered in Manchester, England, is the world’s largest multi-national company dedicated to the recruitment and running of clinical trials at its own research centres across the globe on behalf of its pharmaceutical, biotech and CRO clients. Synexus now has 26 Dedicated Research Centres across the UK, Germany, Austria, Poland, Hungary, Ukraine, Bulgaria, India and South Africa staffed by full-time GCP-trained investigators.
Follow us on Twitter: @SynexusResearch
